← Leaderboards
Yonathan Lissanu
University Of Tx Md Anderson Can Ctr
$6,037,986
Attributed
$6,037,986
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,037,986 · 4
By mechanism
R37$3,279,981 · 1
R01$2,112,899 · 1
R21$645,106 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Rugang Zhang$23,913,209
- Glen Traver Hart$5,258,043
- Min Sup Song$4,833,294
- Michael Richard Green$8,960,138
- Guang Peng$3,599,803
Others in their field
Other Emerging Leaders on “Gene Expression”
- Evan Z Macosko · Broad Institute, Inc.$35,121,158
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$26,358,801
- Benjamin E Deverman · Broad Institute, Inc.$16,920,984
- Tomasz Nowakowski · University Of California, San Francisco$15,628,426
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Crystal Mackall · Children'S Hosp Of Philadelphia$14,040,300
Research focus
Gene ExpressionFutureIn VivoMortalityTumor GrowthBiologicalBiological ModelsXenograft ProcedureNovel TherapeuticsSmall MoleculeGenesCellsTumorCancer EtiologyMediatingChromatinTargeted TreatmentGene TargetingMutantMutateMalignant Neoplasm Of LungMutationImmunotherapySmarca4 Gene
Grant awards (13)
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$952,822
R37 · FY2025 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$537,633
R01 · FY2025 · CA · contact PI
Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors$267,527
R21 · FY2025 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$510,751
R01 · FY2024 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$448,439
R37 · FY2024 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$526,882
R01 · FY2023 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$462,600
R37 · FY2023 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$537,633
R01 · FY2022 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$472,040
R37 · FY2022 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$472,040
R37 · FY2021 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$472,040
R37 · FY2020 · CA · contact PI
Glucocorticoid Receptor degrading bifunctional molecules as therapeutics in prostate cancer$168,779
R21 · FY2019 · CA · contact PI
Glucocorticoid Receptor degrading bifunctional molecules as therapeutics in prostate cancer$208,800
R21 · FY2018 · CA · contact PI